How do Mesoblast’s proprietary Mesenchymal Precursor Cells (MPCs) reduce damaging inflammation and reverse endothelial dysfunction?
Mesoblast’s preclinical studies have shown that MPCs secrete specific factors which convert the pro-inflammatory M1 macrophage to an anti-inflammatory M2 macrophage (a phenomenon termed
macrophage polarization). This results in switching off the production of damaging inflammatory factors.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-249
-
- There are more pages in this discussion • 17,534 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
0.000(0.00%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.03 | $1.04 | $1.02 | $1.047M | 1.008M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 10003 | $1.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 41942 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 38096 | 1.015 |
15 | 145898 | 1.010 |
19 | 235195 | 1.005 |
40 | 732155 | 1.000 |
6 | 69481 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 12985 | 1 |
1.025 | 39520 | 7 |
1.030 | 37034 | 9 |
1.035 | 17525 | 7 |
1.040 | 93796 | 8 |
Last trade - 10.13am 24/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online